Alternative splicing downstream of EMT enhances phenotypic plasticity and malignant behaviour in colon cancer

  1. Tong Xu
  2. Mathijs Verhagen
  3. Rosalie Joosten
  4. Wenjie Sun
  5. Andrea Sacchetti
  6. Leonel Munoz Sagredo
  7. Véronique Orian-Rousseau
  8. Riccardo Fodde  Is a corresponding author
  1. Erasmus MC, Netherlands
  2. Institute Curie, France
  3. Karlsruhe Institute of Technology, Germany

Abstract

Phenotypic plasticity allows carcinoma cells to transiently acquire the quasi-mesenchymal features necessary to detach from the primary mass and proceed along the invasion-metastasis cascade. A broad spectrum of epigenetic mechanisms is likely to cause the epithelial-to-mesenchymal (EMT) and mesenchymal-to-epithelial (MET) transitions necessary to allow local dissemination and distant metastasis. Here, we report on the role played by alternative splicing (AS) in eliciting phenotypic plasticity in epithelial malignancies with focus on colon cancer. By taking advantage of the coexistence of subpopulations of fully epithelial (EpCAMhi) and quasi-mesenchymal and highly metastatic (EpCAMlo) cells in conventional human cancer cell lines, we here show that the differential expression of ESRP1 and other RNA-binding proteins (RBPs) downstream of the EMT master regulator ZEB1, alters the AS pattern of a broad spectrum of targets including CD44 and NUMB, thus resulting in the generation of specific isoforms functionally associated with increased invasion and metastasis. Additional functional and clinical validation studies indicate that both the newly identified RBPs and the CD44s and NUMB2/4 splicing isoforms promote local invasion and distant metastasis and are associated with poor survival in colon cancer. The systematic elucidation of the spectrum of EMT-related RBPs and AS targets in epithelial cancers, apart from the insights in the mechanisms underlying phenotypic plasticity, will lead to the identification of novel and tumor-specific therapeutic targets.

Data availability

The RNA-sequencing data from this study have been submitted to the Gene Expression Omnibus (GEO) database under the accession number GSE192877. Other data referenced in this study are publicly available and can be accessed from the GEO using GSE154927, GSE154730 and Synapse using identifier syn2623706 .

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Tong Xu

    Department of Pathology, Erasmus MC, Rotterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  2. Mathijs Verhagen

    Department of Pathology, Erasmus MC, Rotterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3126-8379
  3. Rosalie Joosten

    Department of Pathology, Erasmus MC, Rotterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  4. Wenjie Sun

    Laboratory of Genetics and Developmental Biology, Institute Curie, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Andrea Sacchetti

    Department of Pathology, Erasmus MC, Rotterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  6. Leonel Munoz Sagredo

    Institute of Biological and Chemical Systems - Functional Molecular Systems (IBCS FMS), Karlsruhe Institute of Technology, Karlsruhe, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Véronique Orian-Rousseau

    Institute of Biological and Chemical Systems - Functional Molecular Systems (IBCS FMS), Karlsruhe Institute of Technology, Karlsruhe, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Riccardo Fodde

    Department of Pathology, Erasmus MC, Rotterdam, Netherlands
    For correspondence
    r.fodde@erasmusmc.nl
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9839-4324

Funding

China Scholarship Council (201806300047)

  • Tong Xu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All mice experiments were implemented according to the Code of Practice for Animal Experiment in Cancer Research from the Netherlands Inspectorate for Health Protections, Commodities and Veterinary Public Health. Permit number AVD1010020171344.

Copyright

© 2022, Xu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,626
    views
  • 254
    downloads
  • 12
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Tong Xu
  2. Mathijs Verhagen
  3. Rosalie Joosten
  4. Wenjie Sun
  5. Andrea Sacchetti
  6. Leonel Munoz Sagredo
  7. Véronique Orian-Rousseau
  8. Riccardo Fodde
(2022)
Alternative splicing downstream of EMT enhances phenotypic plasticity and malignant behaviour in colon cancer
eLife 11:e82006.
https://doi.org/10.7554/eLife.82006

Share this article

https://doi.org/10.7554/eLife.82006

Further reading

    1. Cancer Biology
    Ruijing Tang, Luobin Guo ... Xiaolong Liu
    Research Article

    Tumor neoantigen peptide vaccines hold potential for boosting cancer immunotherapy, yet efficiently co-delivering peptides and adjuvants to antigen-presenting cells in vivo remains challenging. Virus-like particle (VLP), which is a kind of multiprotein structure organized as virus, can deliver therapeutic substances into cells and stimulate immune response. However, the weak targeted delivery of VLP in vivo and its susceptibility to neutralization by antibodies hinder their clinical applications. Here, we first designed a novel protein carrier using the mammalian-derived capsid protein PEG10, which can self-assemble into endogenous VLP (eVLP) with high protein loading and transfection efficiency. Then, an engineered tumor vaccine, named ePAC, was developed by packaging genetically encoded neoantigen into eVLP with further modification of CpG-ODN on its surface to serve as an adjuvant and targeting unit to dendritic cells (DCs). Significantly, ePAC can efficiently target and transport neoantigens to DCs, and promote DCs maturation to induce neoantigen-specific T cells. Moreover, in mouse orthotopic liver cancer and humanized mouse tumor models, ePAC combined with anti-TIM-3 exhibited remarkable antitumor efficacy. Overall, these results support that ePAC could be safely utilized as cancer vaccines for antitumor therapy, showing significant potential for clinical translation.

    1. Cancer Biology
    Elazar Besser, Anat Gelfand ... David Meiri
    Research Article

    In T-cell acute lymphoblastic leukemia (T-ALL), more than 50% of cases display autoactivation of Notch1 signaling, leading to oncogenic transformation. We have previously identified a specific chemovar of Cannabis that induces apoptosis by preventing Notch1 maturation in leukemia cells. Here, we isolated three cannabinoids from this chemovar that synergistically mimic the effects of the whole extract. Two were previously known, cannabidiol (CBD) and cannabidivarin (CBDV), whereas the third cannabinoid, which we termed 331-18A, was identified and fully characterized in this study. We demonstrated that these cannabinoids act through cannabinoid receptor type 2 and TRPV1 to activate the integrated stress response pathway by depleting intracellular Ca2+. This is followed by increased mRNA and protein expression of ATF4, CHOP, and CHAC1, which is hindered by inhibiting the upstream initiation factor eIF2α. The increased abundance of CHAC1 prevents Notch1 maturation, thereby reducing the levels of the active Notch1 intracellular domain, and consequently decreasing cell viability and increasing apoptosis. Treatment with the three isolated molecules resulted in reduced tumor size and weight in vivo and slowed leukemia progression in mice models. Altogether, this study elucidated the mechanism of action of three distinct cannabinoids in modulating the Notch1 pathway, and constitutes an important step in the establishment of a new therapy for treating NOTCH1-mutated diseases and cancers such as T-ALL.